Skip To Main Content
Pre-Clinical Development on Muck Rack

Pre-Clinical Development

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Pre-Clinical

Contact Pre-Clinical, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Patient-derived organoids: an emerging platform to de-risk immunotherapy development

|
By Sylvia F. Boj, Andrea Bisso, Pre-Clinical Development, Gadeta BV
| insights.bio
Recent advances in cancer immunotherapy have had a positive impact on the life expectancy of patients with liquid cancers. With new treatment strategies and druggable targets being identified at an increasing pace, the number of patients eligible for cancer immunotherapy is expected to expand rapidly. However, promising therapeutic developments face hurdles in translating preclinical findings into therapy since conventional 2D cancer models hold low clinical predictive value.
Open in Who Shared Issue with article?
See all 1 articles